Skip to content

Virtual Reality Training in Occupational Rehabilitation

Work-related Attention Bias Modification Training and Virtual Reality Training in Occupational Rehabilitation: A Multisite Pilot Study

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06410794
Enrollment
100
Registered
2024-05-13
Start date
2022-01-01
Completion date
2026-01-01
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety Disorders, Back Pain, Low, Depression, Mental Health Disorder, Musculoskeletal Diseases

Keywords

Virtual reality, gaming, occupational rehabilitation, patient experience, quanitative study, qualitative study

Brief summary

Work-related attention bias modification training and virtual reality training in occupational rehabilitation is a multisite pilot study. The quantitative aim of this pilot study is to compared virtual reality (VR) training and attention bias modication (ABM) training to investigate whether the different training forms result in different results measured with work-related outcomes and cognitive outcomes. The qualitative aim of this pilot study is to investigate the patients' experiences with the usage of VR. Three rehabilitation insitutions will be recruiting patients participating in occupational rehabilitation, and the study will compare the outcomes of work-related interventions with and without the addition of ABM or VR training. The study seeks to determine if these interventions can improve work ability, reduce symptoms of depression and anxiety, and change attentional bias from negative to positive stimuli.

Interventions

DEVICEVirtual Reality with Beat Saber

The VR activity used in the intervention was an add-on activity that did not replace any other activities in the programme. The off-the-shelf product Beat Saber (Beat Games, Prague, The Czech Republic) is the VR game of choice in our study. In collaboration with the participating clinics a systematic VR activity plan will be developed. This includes the selection of games and designing a plan that is interesting and motivating both for patients and clinicians.

Sponsors

Norwegian National Advisory Unit on Occupational Rehabilitation
CollaboratorUNKNOWN
Molde University College
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

This is a non-randomised controlled experiment where we aim to recruit 20 patients from each of the six clinics involved in ABM training and up 100 from each of the clinics involved in VR. That is, 10 receiving ABM training and 10 in the control group, and 60 receiving VR and 40 in the control group. The participants will complete the questionnaires and cognitive measures one the day of arrival and on the penultimate or ultimate day of the rehabilitation/treatment. The measures will take approximately one hour to complete at each measurement point and will not interfere with the participation in the rehabilitation/treatment. In the qualitative part of this pilot, it is aimed to recruit 15 patients, five at each of the three clinics.

Eligibility

Sex/Gender
ALL
Age
18 Years to 67 Years
Healthy volunteers
No

Inclusion criteria

* Age between 18 - 67 years * Must be on sick leave, work assessment allowance or on disability pension * Receiving work-related rehabilitation or treatment at clinics with either an International Classification of Primary Care, Second edition (ICPC-2) within the musculoskeletal (L), psychiatric (P) or unspecific disorders (A) categories or International Classification Disorders-10 diagnosis within the mental and behavioral disorders (F), Diseases of the musculoskeletal system and connective tissue (M) or other diagnoses.

Exclusion criteria

* Applying for a full disability pension; * Unable to complete the measures and receive instructions in Norwegian.

Design outcomes

Primary

MeasureTime frameDescription
Increase work abilityBaseline and discharge (four weeks), and 6 and 12 months after dischargeSelf-reported questionnaire measures, (Work Ability Scale). Work ability: Self-rated work ability was assessed using a single-item question to determine the WAS; this question was published by Gould et al. as part of the full work ability index (WAI). The question used by this study to measure WAS (current work ability compared with your lifetime best) used a scale of 0 to 10 (0 = completely unable to work and 10 = work ability at its best). The following measurement classification from Gould et al. \[46\] was used: poor (0 to 5), moderate (6 to 7), good (8 to 9) and excellent (10).
Reduced depression and anxietyBaseline and discharge (four weeks)Self-reported questionnaire measure, (The Hospital Anxiety And Depression Scale).
Increase expectations to return to workBaseline and discharge (four weeks), and 6 and 12 months after dischargeSelf-reported questionnaire measures, (Return-to-Work Expectation)

Secondary

MeasureTime frameDescription
Increased cognitive performance and attentionBaseline and discharge (four weeks)Computerized cognitive measures. \- Rapid Visual Information Processing (Cambridge Cognition, 2020). The mean response latency on trials where the subject responded correctly. Calculated across all assessed trials.
Patients's experiences in using VRFrom discharge up to 5 month after discharge.Interview guide based on the participants experience.
Increased cognitive performance and memoryBaseline and discharge (four weeks)Computerized cognitive measures. \- Spatial Working Memory (Cambridge Cognition, 2020). The number of times the subject incorrectly revisits a box in which a token has previously been found.
Increased cognitive performanceBaseline and discharge (four weeks)Computerized cognitive measures. \- Stop Signal Task (Cambridge Cognition, 2020). The estimate of time when an individual can successfully inhibit their responses 50% of the time.

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026